Robert E. Claypoole - Jan 10, 2025 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
President and CEO, Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Jan 10, 2025
Transactions value $
$0
Form type
4
Date filed
1/13/2025, 05:24 PM
Previous filing
Jan 12, 2024
Next filing
Jan 14, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise $0 +93.8K $0.00 93.8K Jan 10, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -93.8K -25% $0.00 281K Jan 10, 2025 Class A Common Stock 93.8K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The RSUs shall vest in four equal installments on each of the first four anniversaries of January 10, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.